Roche Holding AG (RHHVF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 22.60 means the share price is 22.60 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $293B is the value of all shares combined. Beta 0.21: the stock has moved about 79% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerRoche Holding AG (RHHVF) trades at $424.75 with MoonshotScore 54/100 (Grade B). Roche Holding AG is a global healthcare company operating in pharmaceuticals and diagnostics. Market cap: $293B, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 15, 2026RHHVF stock analysis for 2026: The stored analyst price target for Roche Holding AG is $470.09; its date is unknown, so no upside or downside is derived from it against the current price of $424.75. The AI MoonshotScore is 54/100, in the Fair band (45-64) — a research signal, not a recommendation. Key factors: analyst coverage, AI-driven quantitative scoring.
RHHVF: 1/3 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Roche Holding AG (RHHVF) Healthcare & Pipeline Overview
Roche Holding AG, a Swiss multinational healthcare company, operates in pharmaceuticals and diagnostics, offering a diverse portfolio of products for oncology, immunology, and infectious diseases. With a strong focus on research and development and a global presence, Roche competes with major pharmaceutical companies in a rapidly evolving healthcare landscape.
What Is the Investment Thesis for RHHVF?
With a market capitalization of $293B and a profit margin of 20.9%, Roche demonstrates financial stability. The company's dividend yield of 3.06% offers an attractive return for investors. Growth catalysts include expansion in key therapeutic areas like oncology and immunology, as well as advancements in diagnostic technologies. However, potential risks include regulatory challenges, competition from other pharmaceutical giants, and the inherent uncertainty in drug development. The company's beta of 0.21 suggests relatively low volatility compared to the overall market.
Based on FMP financials and quantitative analysis
RHHVF Key Highlights
Market Cap of $293B reflects Roche's significant presence in the healthcare industry.
- P/E ratio of 22.60 indicates the price investors are willing to pay for each dollar of Roche's earnings.
- Profit Margin of 20.9% demonstrates Roche's efficiency in converting revenue into profit.
- Gross Margin of 73.5% showcases Roche's ability to manage production costs effectively.
- Dividend Yield of 3.06% provides a steady income stream for investors.
Who Are RHHVF's Competitors?
RHHVF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ALPMF Astellas Pharma Inc. | $15.45 | -1.28% | $27.7B | — |
| AZN AstraZeneca PLC | $160.61 | +0.61% | $249B | 855-pillar |
| BAYRY Bayer AG | $14.07 | -1.54% | $55.3B | 519-signal |
| BMY Bristol-Myers Squibb Company | $63.34 | -0.64% | $129B | 905-pillar |
| NVSEF Novartis AG | $137.95 | -0.40% | $262B | 559-signal |
| MRK Merck & Co., Inc. | $144.71 | -1.91% | $357B | 745-pillar |
| AMGN Amgen Inc. | $382.47 | -2.25% | $206B | 815-pillar |
| ABBV AbbVie Inc. | $254.98 | +1.62% | $451B | 765-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are RHHVF's Key Strengths?
Diversified product portfolio in pharmaceuticals and diagnostics
- Strong research and development capabilities
- Global presence and distribution network
- High profit margin and financial stability
What Are RHHVF's Weaknesses?
Dependence on key products and patents
- Exposure to regulatory risks and patent expirations
- Competition from other pharmaceutical and diagnostics companies
- Potential for product recalls and liability claims
What Could Drive RHHVF Stock Higher?
Potential FDA approvals for new pharmaceutical products in oncology and immunology.
- Expansion of diagnostic testing capabilities for infectious diseases.
- Strategic collaborations with other companies and research institutions.
- Publication of clinical trial results for novel therapies.
- Growth in emerging markets and personalized medicine.
What Are the Key Risks for RHHVF?
Regulatory challenges and delays in drug approvals.
- Competition from generic drugs and other pharmaceutical companies.
- Patent expirations and loss of exclusivity for key products.
- Economic downturns and healthcare reforms.
- Product recalls and liability claims.
What Are the Growth Opportunities for RHHVF?
- Expansion in Oncology: Roche has a significant presence in the oncology market, which is expected to continue growing due to the increasing incidence of cancer globally. By developing and commercializing new cancer therapies, Roche can capitalize on this growth opportunity. The global oncology market is projected to reach $300 billion by 2028.
- Advancements in Diagnostics: The diagnostics market is driven by technological advancements and the need for accurate and timely disease detection. Roche can leverage its expertise in diagnostics to develop innovative solutions for various diseases, including infectious diseases and cardiovascular conditions. The global diagnostics market is expected to reach $120 billion by 2027.
- Strategic Collaborations: Roche can pursue strategic collaborations with other companies and research institutions to expand its product portfolio and access new technologies. The research collaboration agreement with Synlogic, Inc. for the treatment of inflammatory bowel disease (IBD) exemplifies this approach. These collaborations can accelerate the development of innovative therapies and diagnostic solutions.
- Emerging Markets: Roche can expand its presence in emerging markets, where there is a growing demand for healthcare products and services. By tailoring its products and services to meet the specific needs of these markets, Roche can tap into new growth opportunities. Emerging markets are expected to contribute significantly to the growth of the global healthcare industry.
- Personalized Medicine: The rise of personalized medicine presents a significant growth opportunity for Roche. By developing diagnostic tests that can identify patients who are most likely to benefit from specific therapies, Roche can improve treatment outcomes and reduce healthcare costs. Personalized medicine is expected to revolutionize the healthcare industry.
What Threats Does RHHVF Face?
- Increasing competition from generic drugs
- Stringent regulatory requirements and pricing pressures
- Economic downturns and healthcare reforms
- Technological disruptions and cybersecurity threats
What Are RHHVF's Competitive Advantages?
- Strong brand reputation
- Extensive patent portfolio
- Global distribution network
- Expertise in both pharmaceuticals and diagnostics
- High barriers to entry in the pharmaceutical and diagnostics industries
What Does RHHVF Do?
Founded in 1896 in Basel, Switzerland, by Fritz Hoffmann-La Roche, Roche Holding AG initially focused on producing standardized pharmaceuticals. Over the decades, Roche has evolved into a global leader in both pharmaceuticals and diagnostics. The company's pharmaceutical division develops and markets drugs for various therapeutic areas, including oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune conditions, and transplantation. Key products include treatments for cancer, multiple sclerosis, and influenza. Roche's diagnostics division provides in vitro tests for diagnosing diseases such as cancer, cardiovascular conditions, diabetes, COVID-19, hepatitis, and human papillomavirus. This division also supplies diagnostic instruments and reagents to hospitals, laboratories, and point-of-care settings. Roche operates in Switzerland, Germany, the United States, and internationally, maintaining a significant global presence through subsidiaries and partnerships. The company's research and development efforts are central to its strategy, with ongoing investments in innovative therapies and diagnostic solutions. Roche has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD).
What Products and Services Does RHHVF Offer?
- Develops and markets pharmaceutical products for various therapeutic areas.
- Offers in vitro tests for the diagnosis of various diseases.
- Supplies diagnostic instruments and reagents to hospitals and laboratories.
- Conducts research and development to discover new therapies and diagnostic solutions.
- Collaborates with other companies and research institutions to expand its product portfolio.
- Operates in Switzerland, Germany, the United States, and internationally.
How Does RHHVF Make Money?
- Develops and commercializes pharmaceutical products.
- Manufactures and sells diagnostic instruments and reagents.
- Provides diagnostic testing services.
- Generates revenue through product sales and service fees.
What Industry Does RHHVF Operate In?
Roche Holding AG operates in the highly competitive pharmaceutical and diagnostics industry. The global pharmaceutical market is characterized by intense research and development, stringent regulatory requirements, and patent protection. Key trends include the rise of personalized medicine, the increasing prevalence of chronic diseases, and the growing demand for diagnostic testing. Roche competes with major pharmaceutical companies such as AstraZeneca (AZN) and Bayer (BAYRY). The diagnostics market is driven by technological advancements and the need for accurate and timely disease detection.
Who Are RHHVF's Key Customers?
- Hospitals and clinics
- Laboratories
- Healthcare providers
- Research institutions
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● Covered by analysts
- ● Reported in CHF, converted to USD
Why 54?
This rating comes from our nine-signal model, which produces a score but not a per-factor breakdown. The sector-relative five-pillar model, which explains its own contributions, does not cover this listing yet. How the score is built →
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 54 |
| 2026-08-26 | 54 |
| 2026-08-29 | 54 |
| 2026-09-01 | 54 |
| 2026-09-04 | 54 |
| 2026-09-07 | 54 |
| 2026-09-10 | 54 |
What changed?
The score has stayed at 54.
Over the same 18 days the stock moved -8.7%.
Earnings Track Record
Roche Holding AG has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 1.7% above estimates on average.
Financial Health
Roche Holding AG's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 5.47 places it in the safe zone, indicating low near-term bankruptcy risk.
Key Financial Metrics
Return on equity for Roche Holding AG stands at 37.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 12.6%, showing how much profit it generates from its asset base. RHHVF trades at a trailing price-to-earnings ratio of 22.60, roughly in line with the Healthcare sector average of ~21.50x. Its free cash flow yield is 5.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.23 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.3%, the inverse of the P/E and a quick read on earnings relative to price.
Roche Holding AG (RHHVF) Valuation Context
Valued at $293B, RHHVF is classified as a mega-cap stock. Relative to its peer group, RHHVF's quantitative score of 54/100 is below the peer average of 73/100.
RHHVF Revenue & Earnings Trend
In Q2 FY2026, RHHVF generated $37.01B in top-line revenue, marking a sequential decrease of 1.3%. The company recorded net income of $8.38B, with diluted EPS of $10.35. Revenue has contracted over three consecutive quarters, which investors in this mega-cap Healthcare stock should monitor closely. Across the four most recent quarters, RHHVF averaged $8.28 in diluted EPS.
Company Profile
Roche Holding AG operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Basel, CH. The company is led by CEO Thomas Schinecker. RHHVF has traded publicly since 2009.
RHHVF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Diversified product portfolio in pharmaceuticals and diagnostics
- Strong research and development capabilities
- Global presence and distribution network
- High profit margin and financial stability
Bear Case
- Dependence on key products and patents
- Exposure to regulatory risks and patent expirations
- Competition from other pharmaceutical and diagnostics companies
- Potential for product recalls and liability claims
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $37.01B | $8.38B | $10.35 |
| Q4 FY2025 | $37.49B | $6.71B | $8.36 |
| Q2 FY2025 | $39.04B | $9.08B | $11.31 |
| Q4 FY2024 | $38.78B | $2.47B | $3.09 |
Q2 FY2026 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from CHF at today's rate
RHHVF Latest News
-
AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
Zacks · Sep 10, 2026
-
Revolution Medicines Got Its Breakthrough—What Moves It Next?
MarketBeat · Sep 4, 2026
-
Novartis Just Cruised Past A Buy Point Amid Its Roche, Sanofi Rivalry
Yahoo! Finance: RHHVF News · Sep 1, 2026
-
Roche Commits $75 Million in Blood-Cancer Deal Worth Up to $1.53 Billion
Yahoo! Finance: RHHVF News · Sep 1, 2026
RHHVF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for RHHVF.
Price Targets
Consensus target: $470.09
RHHVF MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. RHHVF scores 54/100 (Grade B): the number comes from the legacy nine-factor engine (quantitative signals from revenue growth to news sentiment), written once, not refreshed.
Latest News
AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
Revolution Medicines Got Its Breakthrough—What Moves It Next?
Novartis Just Cruised Past A Buy Point Amid Its Roche, Sanofi Rivalry
Roche Commits $75 Million in Blood-Cancer Deal Worth Up to $1.53 Billion
Leadership: Thomas Schinecker
CEO
Thomas Schinecker is the CEO of Roche Holding AG. His career within Roche spans several leadership roles, demonstrating a deep understanding of the company's operations and strategic direction. Prior to becoming CEO, he held key positions in the diagnostics division, contributing to its growth and innovation. His expertise lies in driving performance and fostering a culture of innovation within the organization. He is responsible for managing over 100,000 employees globally.
Track Record: Under Thomas Schinecker's leadership, Roche has continued to focus on innovation and strategic growth. Key achievements include navigating the evolving healthcare landscape and driving advancements in personalized medicine. His strategic decisions have contributed to the company's strong financial performance and market position. He continues to focus on driving growth in key therapeutic areas and diagnostic solutions.
RHHVF OTC Market Information
The OTC Other tier, where Roche Holding AG (RHHVF) trades, represents a segment of the over-the-counter (OTC) market with minimal listing requirements. Companies in this tier often do not meet the minimum financial standards required for listing on major exchanges like the NYSE or NASDAQ. This tier is generally considered to have the least stringent requirements compared to OTCQX and OTCQB, leading to potentially higher risks for investors due to less available information and oversight. Trading on the OTC Other tier does not necessarily indicate a company is illegitimate, but it signals a need for increased due diligence.
- OTC Tier: OTC Other
- Limited Information: OTC Other stocks often have limited financial disclosures, making it difficult to assess the company's financial health.
- Lower Liquidity: Reduced trading volume can lead to wider bid-ask spreads and increased price volatility.
- Regulatory Scrutiny: OTC stocks are subject to less regulatory oversight compared to exchange-listed stocks.
- Potential for Fraud: The OTC market has a higher risk of fraudulent schemes and scams.
- Price Volatility: OTC stocks can experience significant price swings due to lower trading volume and market manipulation.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Check for any legal or regulatory issues involving the company.
- Review the company's OTC Markets profile for disclosures and compliance.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC trading.
- Established Business: Roche Holding AG has a long history and a strong reputation in the healthcare industry.
- Global Operations: The company operates in multiple countries and has a significant global presence.
- Regulatory Compliance: Roche Holding AG is subject to regulatory oversight in various jurisdictions.
- Financial Stability: The company has a high market cap and a solid financial performance.
- Dividend Payments: Roche Holding AG pays dividends to its shareholders, indicating financial stability.
RHHVF Healthcare Stock FAQ
What does the AI Score mean for RHHVF?
RHHVF holds an AI Score of 54/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. The number comes from the legacy nine-factor engine (quantitative signals from revenue growth to news sentiment), written once, not refreshed. Roche Holding AG is a global healthcare company operating in pharmaceuticals and diagnostics.
Is RHHVF a good stock?
Stock Expert AI does not rate RHHVF buy, sell or hold. Roche Holding AG carries a MoonshotScore of 54/100 on the legacy nine-factor engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about RHHVF stock?
Analyst consensus on Roche Holding AG (RHHVF) is generally positive, reflecting the company's strong market position and diversified healthcare portfolio. Key valuation metrics, such as the P/E ratio and dividend yield, are closely monitored.
What are the key factors to evaluate for RHHVF?
Roche Holding AG (RHHVF) holds a MoonshotScore of 54/100 (moderate). P/E: 22.60x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does RHHVF data refresh on this page?
RHHVF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RHHVF's recent stock price performance?
Roche Holding AG (RHHVF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio in pharmaceuticals and diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RHHVF overvalued or undervalued right now?
Roche Holding AG (RHHVF) trades at 22.60x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of RHHVF?
Yes, most major brokerages offer fractional shares of Roche Holding AG (RHHVF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track RHHVF's earnings and financial reports?
Roche Holding AG (RHHVF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for RHHVF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment decisions should be made based on individual risk tolerance and financial circumstances.